Jardiance Improves Double-Digit Growth Potential With US Approval In CKD
Slight Advantage Over Farxiga In Same Indication
Executive Summary
Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.